COMMUNIQUÉS West-GlobeNewswire

Silo Pharma Announces Share Buyback Program
23/02/2026
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, [...]
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
23/02/2026
VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, [...]
Ultragenyx to Participate at Investor Conferences in March
23/02/2026
NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra [...]
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Smith+Nephew signs distribution agreement with SI-BONE
23/02/2026
Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology [...]
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
23/02/2026
Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics , Inc. (Palvella or “the Company”), a clinical- [...]
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
23/02/2026
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to [...]
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
23/02/2026
FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a [...]
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
24/02/2026
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company [...]
Supernus Pharmaceuticals to Participate in March Investor Conferences
24/02/2026
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Pixel Health Launches One Thread™, an AI-Powered Experience Layer for Unified Patient Access and Engagement
23/02/2026
A collaborative go-to-market approach with Praia Health that accelerates digital front door transformation while keeping health systems in control of their strategy and brand. HOLYOKE, Mass., Feb. 23, 2026 (GLOBE [...]
Enspire Dental Marks Full Transition to Woman-Owned Private Practice Amid Rising Cosmetic Dentistry Demand in Ann Arbor
23/02/2026
Patients increasingly seek cosmetic dentistry, blending confidence with oral health at Enspire Dental. Ann Arbor, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Enspire Dental, a family and general dentistry practice in Ann Arbor, [...]
Foundation for Sarcoidosis Research Receives 2025 RareVoice Award for Federal Advocacy During Rare Disease Month
23/02/2026
CHICAGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has been named a 2025 RareVoice Awards recipient by EveryLife Foundation for Rare Diseases , earning national recognition for [...]
RESTEM to Present at BIO Investment & Growth Summit 2026
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, [...]
Andrzej Lewandowski of Dempster Therapeutic Services Receives Prestigious 2026 ZocDoc Patient Choice Award
23/02/2026
Chicago, IL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Dempster Therapeutic Services is proud to announce that Andrzej Lewandowski , Speech-Language Pathologist and founder, has been honored with the 2026 ZocDoc Patient Choice [...]
IBA – ACQUISITION OF OWN SHARES
23/02/2026
Louvain-la-Neuve, Belgium, February 23 rd , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
23/02/2026
Déclaration de transactions sur actions propres Paris, France (23 février 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que du 16 février 2026 [...]
EssilorLuxottica: Disclosure of transactions in own shares
23/02/2026
Disclosure of transactions in own shares Paris, France (February 23, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that [...]
IBA – ACQUISITION D’ACTIONS PROPRES
23/02/2026
Louvain-la-Neuve, Belgique, 23 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]

Pages